WO2025253337 - MONOSPECIFIC AND BISPECIFIC TAU BINDING PROTEINS AND COMPOSITIONS THEREOF

National phase entry is expected:
Publication Number WO/2025/253337
Publication Date 11.12.2025
International Application No. PCT/IB2025/055816
International Filing Date 05.06.2025
Title **
[English] MONOSPECIFIC AND BISPECIFIC TAU BINDING PROTEINS AND COMPOSITIONS THEREOF
[French] PROTÉINES DE LIAISON À TAU MONOSPÉCIFIQUES ET BISPÉCIFIQUES ET COMPOSITIONS ASSOCIÉES
Applicants **
SANOFI
Inventors
BERTRAND, Philippe
CAMERON, Béatrice
DABDOUBI, Tarik
DEVAUD, Catherine
DUJARDIN, Simon
EYQUEM, Stéphanie
LESUISSE, Dominique
MEUNIER, Mireille
MICHOT, Nadine
NAIMI, Souad
SOUBRIER, Fabienne
Priority Data
24305886.4   05.06.2024   EP
24306578.6   27.09.2024   EP
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
译文

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting4295
EPO Filing, Examination, Granting50102
Japan Filing, Examination, Granting3758
South Korea Filing, Examination, Granting5357
USA Filing, Examination, Granting19990
MasterCard Visa
Total: 83,502
Contact Us
Abstract[English] The present disclosure provides binding proteins that target tau, as well as bispecific binding proteins that target tau and a central nervous system protein (e.g., transferrin receptor 1). Also provided is the use of these binding proteins to treat tauopathies.[French] La présente invention concerne des protéines de liaison qui ciblent tau, ainsi que des protéines de liaison bispécifiques qui ciblent tau et une protéine du système nerveux central (p. ex. le récepteur 1 de la transferrine). L'invention concerne également l'utilisation de ces protéines de liaison pour traiter des tauopathies.